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Natasha M. DeVore and Emily E. Scott1
From the Department of Medicinal Chemistry, The University of Kansas, Lawrence, Kansas 66045
Background: Cytochromes P450 2A13 and 2A6 are involved in nicotine metabolism and tobacco-related lung cancer
initiation.
Results: CYP2A13 and CYP2A6 structures were solved with nicotine and CYP2A13 with NNK.
Conclusion: Structure series reveals basis for nicotine and NNK selectivity and access to buried active site.
Significance: Understanding CYP2A binding and oxidation of pharmacological substrates can aid in drug development
efforts.
Cytochromes P450 (CYP) from the 2A subfamily are known
for their roles in the metabolism of nicotine, the addictive
agent in tobacco, and activation of the tobacco procarcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK).
Although both the hepatic CYP2A6 and respiratory CYP2A13
enzymes metabolize these compounds, CYP2A13 does so with
much higher catalytic efficiency, but the structural basis for this
has been unclear. X-ray structures of nicotine complexes with
CYP2A13 (2.5 Å) and CYP2A6 (2.3 Å) yield a structural rationale for the preferential binding of nicotine to CYP2A13. Additional structures of CYP2A13 with NNK reveal either a single
NNK molecule in the active site with orientations corresponding to metabolites known to form DNA adducts and initiate lung
cancer (2.35 Å) or with two molecules of NNK bound (2.1 Å): one
in the active site and one in a more distal staging site. Finally, in
contrast to prior CYP2A structures with enclosed active sites,
CYP2A13 conformations were solved that adopt both open and
intermediate conformations resulting from an ⬃2.5 Å movement of the F to G helices. This channel occurs in the same
region where the second, distal NNK molecule is bound, suggesting that the channel may be used for ligand entry and/or
exit from the active site. Altogether these structures provide
multiple new snapshots of CYP2A13 conformations that
assist in understanding the binding and activation of an
important human carcinogen, as well as critical comparisons
in the binding of nicotine, one of the most widely used and
highly addictive drugs in human use.

* This work was supported, in whole or in part, by National Institutes of Health
Grant GM076343.
The atomic coordinates and structure factors (codes 4EJG, 4EJH, 4EJI, and 4EJJ)
have been deposited in the Protein Data Bank, Research Collaboratory for
Structural Bioinformatics, Rutgers University, New Brunswick, NJ
(http://www.rcsb.org/).
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Lung cancer is responsible for more deaths than any other
cancer (1). Although the highest risk factor for lung cancer is
cigarette smoking, 19.3% of adults in the United States smoke
cigarettes (2). Much of the difficulty in smoking cessation is the
addictive properties of nicotine (3). Upon inhalation of tobacco
smoke, nicotine rapidly circulates systemically via the bloodstream, with the majority of nicotine metabolism occurring in
the liver via cytochrome P450 (CYP)2 2A6 (3). In addition to
nicotine, tobacco smoke also contains several procarcinognic
nitrosamines with 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) being one of the most prevalent and procarcinogenic (4). NNK is converted to its carcinogenic form by
hydroxylation of either carbon ␣ to the nitrosamino group
(5–7) with the resulting metabolites forming DNA adducts,
often in tumor suppressor or proto-oncogenes like Ras and p53
(8). In humans, both the hepatic CYP2A6 and CYP2A13 in the
respiratory tract can activate NNK to some extent, but
CYP2A13 does so with 61- to 214-fold greater catalytic efficiency than CYP2A6 (7, 9). Activation of NNK in the lung
results in DNA adducts and lung tumors in mice (10) and is
thought to be a potent determinant for lung adenocarcinoma in
smokers. The catalytic efficiency of CYP2A13 with nicotine is
also 22-fold higher than CYP2A6 (11), although rapid nicotine
distribution suggests that hepatic CYP2A6 is likely primarily
responsible for most phase I metabolism of nicotine in vivo (3).
Although the CYP2A6 and CYP2A13 enzymes are 94% identical, the bases for differential binding and metabolism of nicotine and NNK are unknown.
Structures are available for CYP2A6 with the largely in vitro
substrate coumarin and inhibitors (12–14) and of CYP2A13
bound to the in vitro substrate indole or inhibitor pilocarpine
(14, 15). However, no structures are available for substrates
with significant pharmacological relevance, much less the key
addictive and procarcinogenic agents in tobacco. Several studies have used existing CYP2A13 structures as a basis for docking studies to predict NNK binding in CYP2A13 (15–18). In
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part to test these predictions, we have determined structures of
human CYP2A13 bound to NNK by x-ray crystallography. In
addition, we sought to investigate the structural differences in
nicotine binding between CYP2A13 and CYP2A6 by determining the structures of both complexes. In total, four new crystal
structures with these ligands not only identify amino acid residues important for the functional differences between these
two enzymes in the binding and metabolism of nicotine and
biotransformation of NNK into a carcinogen, but they also provide unexpected evidence for multiple ligand binding modes
and the location of a channel in CYP2A13 that may allow ligand
access/egress. The compilation of these structural vignettes is a
stop motion perspective on CYP2A enzyme conformational
changes controlling the binding and metabolism of nicotine
and NNK, two substrates responsible for human tobacco addiction and lung cancer.

EXPERIMENTAL PROCEDURES
Chemicals and Reagents—(S)-Nicotine (Sigma-Aldrich),
NNK (Toronto Research Chemicals, Toronto, Canada), and
Anatrace detergents (Affymetrix, Maumee, OH) were obtained
as indicated.
Protein Expression, Purification, and Crystallization—Truncated, His-tagged human CYP2A6 and CYP2A13 were
expressed recombinantly in Escherichia coli, purified as
described (14, 15, 19), and crystallized using hanging drop
vapor diffusion.
CYP2A6/Nicotine—The CYP2A6/nicotine crystal was grown
from a drop formed by mixing 200 M CYP2A6 with 50 mM
nicotine in potassium phosphate buffer (50 mM potassium
phosphate, pH 7.4, 20% glycerol, 1 mM EDTA, 0.5 M NaCl) 1:1
with precipitant solution A (30% PEG 3350, 0.175 M Tris, pH
8.5, and 0.2 M ammonium sulfate) and then equilibrated against
the same precipitant solution. The crystal was immersed in a
7:3 mixture of synthetic mother liquor and ethylene glycol and
flash-cooled in liquid nitrogen.
CYP2A13/Nicotine—CYP2A13/nicotine crystals were grown
from a drop consisting of 200 M CYP2A13 with 50 mM nicotine in potassium phosphate buffer and 2% Anapoe-35, mixed
2:1 with precipitant solution A and cryoprotected as above.
CYP2A13/NNK in P1 Space Group—Crystals were grown
from a drop consisting of 200 M CYP2A13 with 50 mM NNK in
potassium phosphate buffer and 0.2% Triton X-405, mixed 2:1
with precipitant solution A and cryoprotected as above.
CYP2A13/NNK in I422 Space Group—CYP2A13 (33.5 nmol)
with 50 mM NNK was mixed 1:1 with cytochrome b5 in a phosphate/sucrose buffer (0.25 M potassium phosphate, 0.5 M
sucrose), concentrated to 1 ml, and run on a size exclusion
column (Superdex 200; GE Healthcare) in the same buffer. The
complex eluted in the void volume and was concentrated to
⬃500 M. The crystals grew from a 2-l drop containing this
protein solution mixed 1:1 with precipitant solution B (4.0 M
sodium formate, pH 7.8). The cryoprotectant consisted of 6 M
sodium formate.
Data Collection, Molecular Replacement, Refinement, and
Validation—Native data sets were collected at the Stanford
Synchrotron Radiation Lightsource (Stanford, CA) on Beamlines 9-2 or 11-1 using a 0.98 Å wavelength at a temperature of
AUGUST 3, 2012 • VOLUME 287 • NUMBER 32

100 K. The data were processed using Mosflm and Scala (20, 21)
with the statistics shown (Table 1). All four structures were
solved by molecular replacement using Phaser (21).
The search model for the CYP2A6 nicotine complex was a
CYP2A6 inhibitor structure (Protein Data Bank code 2FDV)
(12). The search model for the CYP2A13 nicotine complex was
CYP2A6 with coumarin (Protein Data Bank code 1Z10) (13).
Six CYP2A13 molecules (molecules A–F) were initially located
by molecular replacement (Matthews coefficient 3.88 and 68%
solvent). However, it was readily apparent upon examination of
the crystal packing and initial electron density maps that two
additional molecules of CYP2A13 were present, and they were
manually added to the overall model as molecules G and H
(Matthews coefficient 2.91 and 57% solvent). These two additional molecules clearly had alterations in the placement of the
F, F⬘, G⬘, and G helices, resulting in a more open conformations
of CYP2A13, which is likely why they were not identified by
molecular replacement originally. The original six CYP2A13
molecules (A–F) were closed, with four (A–D) containing electron density in the active site that could clearly be modeled as
nicotine (see Fig. 1B). Two of the closed molecules (E and F) did
not have sufficient electron density in the 2兩Fo兩 ⫺ 兩Fc兩 map at 1 
to model nicotine.
For the CYP2A13/NNK P1 structure, the search models were
CYP2A6 bound to coumarin (Protein Data Bank code 1Z10)
(13) and molecule G from the CYP2A13/nicotine structure
above. As in the case with the CYP2A13/nicotine structure, six
molecules (A–F) were in the closed conformation, and two
molecules (G and H) were in more open conformations. Molecules A–F all had clear electron density for NNK in the active
sites.
The search model for the CYP2A13/NNK I422 structure was
CYP2A13 (Protein Data Bank code 2P85) (15). Although a solution initially containing a 1:1 ratio of CYP2A13 to cytochrome
b5 was used to grow the crystals, and density weakly suggestive
of cytochrome b5 was present in the channels of the P450 crystalline lattice, it was not strong enough to model cytochrome b5.
Model building and refinement were accomplished iteratively using COOT (22) and Refmac5 (23) in the CCP4i suite
(21). Validation was accomplished using WHAT_CHECK (24)
and PROCHECK (25). Refinement and Ramachandran plot statistics are in Table 1. Coordinates have been submitted to the
Protein Data Bank (CYP2A6/nicotine, Protein Data Bank code
4EJJ; CYP2A13/nicotine, Protein Data Bank code 4EJG;
CYP2A13/NNK (P1), Protein Data Bank code 4EJH; and
CYP2A13/NNK (I422), Protein Data Bank code 4EJI). Probeoccupied voids were defined using VOIDOO (26) with a 1.4 Å
probe and a grid mesh of 0.4 Å as described (19, 27).
Spectral Ligand Binding Assay—The spectral ligand binding
assay was performed as described previously (28, 29). The
results are the averages of two different titrations.
Site-directed Mutagenesis—Internal single and multiple
mutations were made in the modified CYP2A6 gene in the
expression vector pKK2A6dH using synthetic oligonucleotides
that incorporated the desired nucleotide substitutions using
the QuikChange site-directed mutagenesis method as previously reported (19). The proteins were expressed and purified
also as described (19). The specific contents for the CYP2A6
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0.018
1.692
0.339
87.8/11.5/0.4/0.3

0.023
1.915
0.292
90.2/9.4/0.2/0.2

20.3/26.4
15,432/41.2
15,074/41.3
172/32.5
48/56.5
138/36.3

102.58-2.50
156,132
2.91/57.7
Eight (four closed with nicotine,
two closed without nicotine,
and two different open
conformations without
nicotine; mol. G, H)
22.4/28.5
30,625/48.2
30,178/48.3
344/34.7
48/60.4
49/31.9
6/33.3

71.7, 120.3, 153.7
100.6, 100.8, 93.7
117.6-2.5 (2.63-2.50)
2.0 (2.0)
0.066 (0.452)
7.1 (1.8)
96.7 (88.1)
329,774/164,366 (43,876/21,915)

71.2, 194.0, 90.3
90.0, 102.7, 90.0
97.0-2.3 (2.36-2.30)
3.9 (3.9)
0.045 (0.420)
11.9 (1.9)
99.9 (99.9)
409,663/105,683 (30,105/7804)
97.02-2.30
100,359
2.79/55.8
Four (four closed with nicotine)

P1

CYP2A13/nicotine

P1211

CYP2A6/nicotine

The values in parentheses are for the highest resolution shell.

Rwork/Rfree
Number of atoms/B factor
Protein
Heme
Ligand
Water
Glycerol
rmsd
Bond lengths (Å)
Bond angles (°)
Error in coordinates by Luzzati
plot (Å)
Residues in Ramachandran plot
regions: favorable/additional
allowed/generously allowed/
disallowed (%)

Refinement
Resolution (Å)
No. reflections
Matthews coefficient/% solvent
Molecules per asymmetric unit,
details of liganded state and
conformation

Data collection
Space group
Cell dimensions
a, b, c (Å)
␣, ␤, ␥ (°)
Resolution (Å)a
Redundancya
Rpima
Mn(I/sd)a
Completenessa (%)
Total/unique reflectionsa

TABLE 1
CYP2A13 and CYP2A6 data collection and refinement statistics

88.3/11.0/0.4/0.3

0.019
1.694
0.314

69.77-2.35
187,903
2.89/57.4
Eight (six closed with one NNK
each and two different open
conformations similar to
CYP2A13/nicotine; mol. G,
H)
21.4/27.3
30,811/47.9
30,104/48.1
344/34.9
90/65.0
261/38.3
12/47.9

71.7, 119.4, 153.8
100.7, 100.9, 93.6
83.6-2.35 (2.41-2.35)
4.0 (4.0)
0.048 (0.342)
9.3 (2.4)
97.5 (96.7)
787,673/198,013 (57,791/14,523)

P1

CYP2A13/NNK (P1)

91.8/7.8/0.2/0.2

0.024
1.918
0.288

20.1/23.6
3936/40.9
3794/40.8
43/32.3
30/47.1
69/45.1

51.90-2.10
41,386
3.31/62.8
One (two NNK molecules and
closed conformation)

122.8, 122.8, 192.2
90.0, 90.0, 90.0
97.1-2.1 (2.15-2.10)
14.7 (14.8)
0.027 (0.372)
18.3 (2.1)
100.0 (100.0)
639,843/43,580 (46,911/3,175)

I422

2A13/NNK (I422)

Nicotine, Nitrosamine Binding, and Access in Human CYP2A

VOLUME 287 • NUMBER 32 • AUGUST 3, 2012

Nicotine, Nitrosamine Binding, and Access in Human CYP2A

FIGURE 1. Nicotine binding to CYP2A6 (blue) and CYP2A13 (yellow). A and B, CYP2A6 (A, blue ribbons and sticks) and CYP2A13 (B, yellow ribbons and sticks)
with composite omit A-weighted 2兩Fo兩 ⫺ 兩Fc兩 electron density (blue mesh) contoured at 1.0  around nicotine (gray sticks). C, overlay of CYP2A6 and CYP2A13
active sites, colored as in A and B, with important active site residues labeled. All panels show heme as black sticks with a red sphere (iron). The dashed lines
represent hydrogen bonding to Asn-297 or distances from ligand sites of metabolism to the heme iron.

I300F and I300F/G301A mutants were 9.1 and 8.6 nmol/mg. All
of the other proteins had specific contents ⬎13.9 nmol/mg. The
proteins were active in phenacetin O-dealkylation as reported
(19).

RESULTS
Dissociation Constants for Nicotine and NNK—Nicotine and
NNK binding to both CYP2A13 and CYP2A6 resulted in classic
type I spectral shifts indicative of displacement of the ironcoordinated water molecule. NNK bound with similar affinities
to CYP2A13 (Kd ⫽ 4.4 M) and CYP2A6 (Kd ⫽ 1.4 M). In
contrast, the KD for nicotine binding to CYP2A6 was 8.7-fold
higher than to CYP2A13 (Kd values 470 and 54 M, respectively) (30). Because a subset of active site residue substitutions
between these two CYP2A enzymes have proved key in controlling the differential binding and metabolism of other CYP2A
ligands (19, 29), we subsequently explored the effects of
selected mutations on nicotine affinity. For example, substitution of the CYP2A6 Ile-300 residue with the Phe found at this
position in CYP2A13 decreased the nicotine Kd from 470 to 234
M. However, the CYP2A6 I300F/G301A double mutant,
which simultaneously replaces two CYP2A6 residues with the
corresponding CYP2A13 residues, reverts the Kd to 419 M,
suggesting that the contributions of individual mutations are
not simply additive. Simultaneous substitution of four of the
ten active site residues differing between the two wild type
enzymes (CYP2A6 I208S/I300F/G301A/S369G) resulted in a
Kd of 196 M, or ⬃3.6-fold higher than that observed for wild
type CYP2A13. The addition of the V117A substitution further
increases the affinity to 144 M, or ⬃2.6-fold higher Kd than for
the CYP2A13 wild type enzyme.
Structure Determination and Overall Structures—Data collection and refinement statistics for structures determined of
CYP2A13 and CYP2A6 with nicotine and two different structures of CYP2A13 with NNK are provided in Table 1. The four
molecules present in the asymmetric unit of the CYP2A6/nicotine structure were very similar and contained strong density
corresponding to nicotine binding in the active site (Fig. 1A).
The CYP2A13/nicotine structure contained eight molecules
(A–H) with four molecules containing nicotine (Fig. 1B). The
CYP2A13/NNK structure from the P1 space group also contained a total of eight molecules, with six containing NNK. In
both the CYP2A13/nicotine and the CYP2A13/NNK P1 strucAUGUST 3, 2012 • VOLUME 287 • NUMBER 32

tures, molecules G and H had significant relocation of the F, F⬘,
G⬘, and G helices compared with the closed conformation,
yielding intermediate and open conformations, respectively.
The CYP2A13/NNK structure derived from crystallization in
the space group I422 consisted of only one CYP2A13 molecule
in the asymmetric unit. In this case the protein was in the closed
conformation, but with two molecules of NNK present in/near
the active site.
Comparisons among the protein conformations observed in
the different complexes reveal that the backbone structures of
the closed molecules of both CYP2A13 and CYP2A6 are very
similar, regardless of ligand, with an rmsd for core C␣ atoms of
0.25– 0.65 Å. The intermediate conformation called molecule
G in the CYP2A13/nicotine structure is very similar to the
intermediate conformation modeled as molecule G in the
CYP2A13/NNK (P1) structure (C␣ rmsd 0.411 Å). Similarly
the open conformation modeled as molecule H in the
CYP2A13/nicotine structure is very similar to the open conformation modeled as molecule H in the CYP2A13/NNK (P1)
structure (C␣ rmsd 0.488 Å). In contrast, both intermediate and
open conformations are distinct from the closed conformation,
with molecule G having a C␣ rmsd of 0.96 Å compared with the
closed structures and the open conformation molecule H demonstrating an even higher C␣ rmsd of 1.3 Å compared with the
closed structures.
Comparison of CYP2A13 and CYP2A6 with Nicotine—Both
CYP2A13 and CYP2A6 oxidize nicotine at various locations on
the methylpyrrolidine ring. Consistent with this, nicotine binds
with the methylpyrrolidine ring oriented toward the heme in
both enzymes (Fig. 1, A and B). The dominant oxidation reaction for both enzymes is 5⬘-hydroxylation to form 5⬘-hydroxynicotine (31), which is in equilibrium with the nicotine
⌬1⬘(5⬘)-iminium ion and then further oxidized to cotinine and
eliminated in urine (32). However, both enzymes can also oxidize nicotine on the methyl to ultimately generate nornicotine
(31, 33), and at least CYP2A6 is also able to oxidize the 2⬘ position to generate the aminoketone precursor of NNK (34). In the
CYP2A13 complex with nicotine (Fig. 1B), the pyrrolidine is
oriented so that the 5⬘ and methyl carbons are closest to the
heme iron at 4.0 and 5.8 Å, respectively. The pyridine ring of
nicotine forms a 3.2 Å hydrogen bond with Asn-297 in
CYP2A13. In the CYP2A6 nicotine complex (Fig. 1A), the pyrJOURNAL OF BIOLOGICAL CHEMISTRY
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rolidine 5⬘ and methyl carbons are at similar distances from the
heme iron (3.4 and 5.8 Å, respectively), but the 4⬘-carbon is
even closer at only 2.5 Å. Another difference is that in CYP2A6
the pyridine nitrogen is too far (3.8 Å) from Asn-297 for even a
weak hydrogen bonding interaction.
Although the overall orientations of nicotine in the two
active sites are similar, comparison by overlapping them (Fig.
1C) emphasizes the differences in the relative orientations. In
CYP2A13 the methylpyrrolidine ring is oriented more parallel
to the heme plane, whereas in CYP2A6 the orientation is closer
to perpendicular. The sp3 hybridization of C2⬘ and the (S) stereochemistry of the substrate then dictate different planes for the
pyridine rings and differential interactions with Asn-297.
Because Asn-297 is a key orienting feature for the CYP2A active
site with several other ligands (6, 12–15), it is notable that in
CYP2A6 the Asn-297 side chain is rotated slightly farther away
from nicotine compared with the CYP2A13 structure. Differences in the details of nicotine orientation are likely also mediated by several other substantial differences between the two
active sites involving both conserved and nonconserved residues. First, in CYP2A13 the larger Phe at position 300 is nonetheless torsioned away from the active site, providing more
space in this region compared with the Ile at this position in
CYP2A6. This change appears in concert with differential positioning of the conserved Phe-209, which in CYP2A6 occludes
slightly more active site volume than in CYP2A13. Thus residues at both positions 300 and 209 may sequester nicotine
slightly closer to the heme in CYP2A6. Another important difference is observed in the position of the conserved Leu-370
residue. The orientation directly toward nicotine in CYP2A6
would seem to be correlated with the more vertical orientation
of the pyrrolidine ring, whereas rotation of this ring to be more
parallel to the heme in CYP2A13 would be facilitated by the
redirection of Leu-370 away from the active site center as
observed in CYP2A13. Both a preceding Gly only present in
CYP2A13 and/or reduction in the adjacent side chain size at
position 117 from a Val in CYP2A6 to the Ala in CYP2A13 may
facilitate this rotation of Leu-370. In aggregate, these residues
and slight changes caused by residues 365 and 366 result in a
CYP2A13 active site that is larger (330 Å3) compared with that
of CYP2A6 (247 Å3) with the same ligand.
Structures of CYP2A13 with NNK Bound—NNK can be oxidized by CYP2A13 at either carbon ␣ to the nitrosamine. The
dominant metabolite (5, 7, 9) results from hydroxylation of the
␣-methylene, but the ␣-methyl can also be hydroxylated with
about a 3-fold lower Kcat/Km (5, 7, 9). NNK bound to CYP2A13
in two different orientations in different molecules of the
CYP2A13/NNK P1 structure and in yet another orientation in
the CYP2A13/NNK I422 structure. In the P1 structure, the two
NNK orientations were very similar with respect to the placement of the pyridine ring, with the pyridine nitrogen serving as
a hydrogen bond acceptor for Asn-297 (Fig. 2, A and B). As in
the CYP2A13/nicotine structure above, Phe-300 appears to
pack well with the pyridine ring. In contrast, this NNK structure revealed two different orientations of the nitrosamine end
of the substrate. The orientation in Fig. 2A clearly shows the
terminal nitrosamine nitrogen located most directly above the
heme iron with the ␣-methylene and ␣-methyl carbons 4.5 and

26580 JOURNAL OF BIOLOGICAL CHEMISTRY

FIGURE 2. Orientations of NNK (yellow sticks) found in molecules of
CYP2A13. A and B, CYP2A13/NNK orientations most consistent with methylene (A) and methyl (B) oxidation, respectively. C, CYP2A13/NNK I422 structure
showing with two NNK molecules bound. For all panels, NNK is shown as
sticks with yellow carbon atoms, and mesh is the composite omit A-weighted
2兩Fo兩 ⫺ 兩Fc兩 electron density contoured at 1.0  around NNK.

5.3 Å from the heme iron, respectively. The methylene distance
and blocking of the methyl by the nitrosamine bulk in this orientation are consistent with the preference of CYP2A13 for
␣-methylene hydroxylation. In this orientation, the methyl
would have to rotate toward the iron for hydroxylation. The
second NNK orientation in the P1 structure (Fig. 2B) differs
from the first in that the nitrosamine end is torsioned so that
the methyl carbon is very close to the heme iron (2.2 Å) and the
␣-methylene is more distal with a distance of 4.5 Å. A slight
VOLUME 287 • NUMBER 32 • AUGUST 3, 2012
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FIGURE 3. Comparison of CYP2A13 conformations (ribbons) and cavities
(mesh). A, comparison of CYP2A13/NNK in the canonical closed orientation
(blue) and the most open conformation (molecule H, purple). The black arrow
indicates channel with the bulge in the I helix just past the arrow tip. B, stereo
image of active site of A with key side chains (sticks) and active site cavities.
C, stereo image comparison of CYP2A13/NNK open conformation (molecule
H, purple) with CYP2A13/2⫻NNK I422 closed structure (green) reveals the
second NNK molecule is located in space that becomes the base of the channel to the surface in molecule H. D, stereo image comparison of CYP2A13/
NNK P1 closed conformation containing NNK (blue) and the intermediate
conformation (molecule G, pink) reveals in the intermediate conformation
that the primary void is smaller on one side with the I helix shift, Phe-300,

AUGUST 3, 2012 • VOLUME 287 • NUMBER 32

shift of NNK away from the heme would appear to be required
prior to metabolism because the 2.2 Å distance is too close to
allow the simultaneous presence of the catalytic iron(IV) oxo
intermediate. Overall, the active site volumes containing both
of these NNK orientations are similar, ranging from 280 to 306
Å 3.
The I422 crystals yielded a very different scenario for NNK
binding to CYP2A13. NNK in the active site adopts a nonproductive orientation with the pyridine ring coordinated to the
heme iron (Fig. 2C). This NNK molecule maintains a hydrogen
bond to Asn-297, albeit via the nitrosamine oxygen. In addition
to the molecule of NNK interacting directly with the heme iron,
a second molecule of NNK was also present. This second NNK
molecule is more distant from the heme and located above the
K⬘-L loop. The volume occupied by this second NNK was not
available in the P1 CYP2A13/NNK structures. The excess volume becomes available through movement of the Phe-480 side
chain, which rotates to  stack with the pyridine ring of the
second NNK (Fig. 2C). The pyridine nitrogen of this second
NNK is part of a water-bridged hydrogen bonding network to
the backbone carbonyl of Met-368. Reorganization of Phe-480
and a smaller shift of the Met-368 side chain result in an active
site volume of 598 Å3, almost double that observed in the
CYP2A13/NNK P1 crystals, but without significant differences
in the backbone.
Structures of CYP2A13 with an Access/Egress Channel—
Comparison of the overall structures of different CYP2A molecules in the various structures indicates some significant differences. A canonical “closed” conformation is present for
CYP2A6 with nicotine (all four molecules in the asymmetric
unit), for the single molecule in the CYP2A13/2⫻NNK I422
structure and for six of the eight molecules in the CYP2A13/
nicotine and CYP2A13/NNK P1 structures. However, the last
two molecules in the CYP2A13/nicotine and the CYP2A13/
NNK P1 structures were substantially different and appear to
form a series of conformations from open to closed. This potentially indicates a route by which substrates and metabolites
might pass in and out of the otherwise enclosed active site,
although of course these conformational changes could also
occur in the absence of ligand transit.
Molecule H is similar in both the CYP2A13/nicotine and
CYP2A13/NNK P1 structures with an rmsd of 0.488 Å and has
the most pronounced alterations compared with the canonical
closed conformation. The previously enclosed ⬃300 Å3 active
site opens up enough to have a channel all the way to the surface
passing between helix F and the ␤4 sheet (Fig. 3A). At the backbone level, the most significant differences are observed as
shifts in the F, F⬘, G⬘, and G helices away from the heme and a
bulge in helix I over the heme (tip of arrow in Fig. 3A). The
entrance/exit of the channel on the protein exterior is lined
with hydrophilic residues Gln-210, Glu-304, Thr-308, Thr-212,
Asp-218, and His-477. Raising the active site “roof” composed
of the F-G helices, in concert with substantial repositioning of
key side chains, have significant effects on the active site topolPhe-209, and Phe-118 occluding part of the active site but a small new bulge
at the base of the channel to the surface in the open conformation. B and C,
ligands omitted for clarity.
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ogy as well. First, there are substantial changes on either side of
the newly formed exit from the active site proper (Fig. 3B).
Significantly, the F-helix residue Phe-209 is not only shifted
upward by ⬃3 Å along with the whole F helix but also torsioned
away from the new channel. On the opposite side of the new
channel, Phe-480 is torsioned in the opposite direction. The
movement of Phe-480 opens the same large volume observed
over the K⬘-L loop as in the CYP2A13/2⫻NNK I422 structure,
space that was occupied in that case by the second molecule of
NNK (Fig. 3C). Although the cavity is opened up on one face
allowing access to the protein surface, on the opposite face of
the active site adjustments are observed that would serve to
discourage ligand binding. The I helix kink and corresponding
adjustments in the Phe-300 side chain and shifts in Phe-118
toward the active site reduce ligand access to Asn-297 and
occlude volume otherwise occupied by the pyridine rings of
NNK and nicotine. This results in an active site with insufficient
capacity to bind either nicotine or NNK in the orientations
consistent with metabolism of these substrates as observed
herein. Thus this 883 Å3 cavity is the net result of both opening
a channel to the protein surface and simultaneously obscuring
the most distal part of the active site proper, a concerted process for ligand egress akin to getting toothpaste out of the tube
by opening the cap and squeezing from the bottom.
An intermediate protein conformation is observed in the
form of molecule G from both the CYP2A13/nicotine and
CYP2A13/NNK P1 structures. In this case, the overall protein
backbone of G is most similar to the “open” molecule H conformation, but key side chains once again occupy different positions to yield yet another new active site topology. In this case
the resulting enclosed active site cavity is smaller than ever
reported for CYP2A13 (247 Å3; Fig. 3D). The overall decrease in
active site volume is primarily due to a ⬃2 Å bulge of one turn
of the I helix backbone, which repositions Phe-300 and Ala-301
to reduce the volume available near the I helix immediately over
the active site into the cavity (Fig. 3A). Additionally Phe-209
and Phe-118 adopt positions that occlude part of the cavity
normally occupied by substrates in a way very similar to the
“open” conformation in molecule H. Although repositioning of
Phe-209 opens a small volume corresponding to the base of the
channel in molecule H, on the opposite side of where the channel base would be, Phe-480 is still oriented toward the active site
instead of torsioned away as seen when the channel is open.
Thus only the beginning of the channel to the surface is
observed in molecule G.

DISCUSSION
Important Residues for Differential Nicotine and NNK Binding and Metabolism—Differences in the levels and function of
human CYP2A6 have been associated with smoking behavior
and drug clearance (3, 35), and CYP2A13 with lung cancer risk
(36). The human CYP2A enzymes 2A13 and 2A6 are 94% identical at the amino acid sequence level, but there are substantial
differences in their metabolism of the key pharmacologically
important agents in tobacco, primarily the addictive agent nicotine and a key procarcinogen, NNK. Although the primary
nicotine metabolite for both enzymes results from 5⬘-oxidation, CYP2A13 demonstrates 5–23-fold higher in vitro enzy-
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matic efficiency (11, 31). Nicotine also binds to CYP2A13 with
a binding affinity 8.7-fold greater than CYP2A6. Similarly,
although CYP2A13 readily generates carcinogenic metabolites
from hydroxylation at both carbons ␣ to the nitrosamine,
CYP2A6 only does so poorly and at only one of these positions
(9, 37).
The structures of both human CYP2A enzymes presented
herein suggest that these functional differences are related to
important changes in the active sites that affect substrate affinity and height and orientation over the heme. A key interaction
between CYP2A13 and the pyridine rings of both nicotine and
NNK is a hydrogen bond that is not present for CYP2A6 with
nicotine and likely has a substantial contribution to both the
observed enzyme affinities and ligand orientations. Mutation of
Asn-297 in CYP2A6 was noted to increase the Km for coumarin
(38). Structures of CYP2A6 with coumarin and methoxsalen
show that both ligands hydrogen bond to Asn-297 but do so via
a ketone oxygen substituent on a ring system rather than to the
ring system itself, as occurs for nicotine and NNK in CYP2A13.
This is consistent with a steric rationale for nicotine and NNK
positioning (see below).
The overall orientations of nicotine in both active sites are
consistent with metabolism on the pyrrolidine ring. Although
both enzymes can form a minor nornicotine metabolite resulting from methyl hydroxylation, both complexes suggest that a
reorientation might be required to generate this metabolite.
Instead, the primary 5⬘ site of metabolism is positioned more
directly over the iron. Assuming the observed binding orientations are retained during the catalytic cycle, the stabilizing
hydrogen bond between the pyridine nitrogen and Asn-297 and
the orientation of the plane of the pyrrolidine ring in CYP2A13
would appear to present the 5⬘-carbon to a catalytic Fe(IV)⫽O
species with a more favorable geometry for hydrogen abstraction and rebound. The identity and placement of residues at
positions 300, 208, and 209 above the pyridine ring facilitate a
nicotine position slightly higher above the heme in CYP2A13
than is observed in CYP2A6, seemingly enabling the hydrogen
bonding interaction with the heteroatom within the ligand ring
for CYP2A13, but not CYP2A6. The importance of the identity
of the residue at position 300 is also supported by the substantially increased nicotine binding affinity in the CYP2A6 I300F
mutant enzyme. Similarly, changes in the identity and/or position of residues at positions 117, 369, 370, and perhaps 366
nearer the pyrrolidine ring appear to modulate both the vertical
placement of the overall nicotine molecule and the plane of the
pyrrolidine ring and thus the entire molecule. This is also supported by binding studies where incorporation of five CYP2A13
residues into the CYP2A6 active site (CYP2A6 V117A/I208S/
I300F/G301A/S369G) increased the affinity for nicotine from
470 M for the parent CYP2A6 to only ⬃2.6-fold greater (144
M) than wild type CYP2A13 (54 M).
Comparison between structures of CYP2A6 with various
ligands and of CYP2A13 with NNK in productive orientations,
along with site-directed mutagenesis information, suggests
possible reasons why hepatic CYP2A6 does not readily activate
the NNK procarcinogen to initiate liver cancer in smokers.
Although NNK binds to both enzymes with similar affinities,
the orientation of NNK in CYP2A6 may not be consistent with
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metabolism. In particular, the projection of Ile-300 above the
pyridine ring of nicotine in CYP2A6 may also limit the ability of
the NNK pyridine to adopt a position that would facilitate
hydrogen bonding with Asn-297. Other residues identified by
site-directed mutagenesis to alter NNK metabolism include
117 (7), 208 (7), 297 (6), 372 (7), and 465 (7). Most of these
residues appear to play steric roles in the differential binding of
nicotine and likely do so for NNK as well.
The overall orientations of NNK in the CYP2A13/NNK P1
structure are consistent with NNK metabolism, with the nitrosamine end oriented over the heme. One orientation of the
nitrosamine chain is most consistent with ␣-methylene
hydroxylation (4.5 Å from iron) and has the ␣-methyl group
further away. The second orientation of NNK observed in this
structure is more consistent with ␣-methyl hydroxylation
product with the methyl group only 2.2 Å from the heme. However, in this case, the methyl group located very close to the
heme would have to move slightly distally for oxygen to bind
and generate the catalytic species.
These observed orientations of NNK are generally well predicted by docking studies, all of which suggested hydrogen
bonding between the NNK pyridine ring and Asn-297 (6, 7, 15,
18). However, the positions of atoms in the nitrosamine end of
the molecule appear to vary slightly between studies, most of
which showed binding modes for both metabolites (6, 7, 15).
Flexibility in this region is also evident in the structures herein.
Notably, an NNK study by Xu et al. (18) also included molecular
dynamics simulations and specifically stated that poses with the
pyridine ring oriented toward the heme were disregarded
because this pose was not consistent with metabolism. This is
an assumption that may have been made by other studies as
well, yet the CYP2A13/NNK I422 structure described below
indicates that this orientation does exist, despite the fact that
metabolism does not appear to occur from NNK in this
orientation.
Simultaneous Binding of Two NNK Molecules—Surprisingly,
a separate I422 structure of the CYP2A13/NNK complex contained two molecules of NNK: one in a nonproductive orientation in the active site and one more distal from the heme. The
space to bind the distal NNK molecule is made available
through torsion of Phe-480 without significant backbone alterations. The reorientation of this single side chain nearly doubles
the active site volume (598 Å3) from that observed in previous
structures containing a single ligand (⬃300 Å3). This type of
Phe repositioning is very similar to two different structures of
CYP2E1 where repositioning of either Phe-298 or Phe-478 on
opposite sites of the active site can substantially increase the
active site size to accommodate larger ligands (14, 39). Simultaneous binding of more than one ligand has previously been
observed for CYP3A4, CYP2C8, CYP2B4, and CYP21A2 (40 –
43). Unlike the structures of CYP3A4 with ketoconazole (43) or
CYP2C8 with 9-cis-retinoic acid (40), the second NNK ligand
molecule does not pack or interact with the NNK in the active
site. Instead the second molecule of NNK occupies a separate
portion of the active site with the pyridine ring -stacking with
Phe-480. This location is reminiscent of the second molecule of
17␣-hydroxyprogesterone in CYP21A2, which is located in a
channel to the protein surface (41).
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FIGURE 4. Comparison of CYP2A13 conformations. Shown are CYP2A13/
NNK P1 closed (blue), intermediate (pink, molecule G), and open (purple, molecule H) conformations versus CYP2A13/2⫻NNK I422 closed structure (green).
Several phenylalanine residues have substantially different conformations
between molecules. The main difference between the intermediate (pink)
and open (purple) conformation is Phe-480 reorientation.

Monitoring CYP2A13 binding of NNK binding by spectral
shifts that occur upon ligand titration reveal no experimental
evidence for cooperative binding. However binding of the distal
NNK would not be likely to alter the iron-coordinated water
molecule like the more proximal molecule would. Thus spectral
binding shifts may only be responsive to the NNK molecule in
the active site, as has been observed for fluorol-7GA binding to
CYP3A4 (44). Additionally, the proximal NNK molecule in the
nonproductive orientation would be expected to yield a type II
spectral shift because the pyridine nitrogen appears to coordinate to iron, but in solution only a type I spectral shift is
observed, even at high concentrations, when CYP2A13 is
titrated with NNK. Thus it appears that simultaneous binding
of two NNK molecules in this orientation is not the predominant situation in the purified two-component system in solution. However, the space occupied by the distal NNK molecule
over the K-L loop is also observed as part of the void available in
the “open” unliganded molecule H of both the CYP2A13 structures with nicotine and NNK (P1).
Access/Egress Channel—Molecules G and H of both
CYP2A13 P1 structures present two previously undescribed
conformations. Molecule G appears to be an intermediate conformation between the closed CYP2A13 conformation and the
open conformation observed for molecule H. The channel in
molecule H is very similar to the channel observed in CYP2D6
(Protein Data Bank code 2F9Q) where the active site also opens
between the F helix and ␤4 sheet (supplemental Fig. S1) (17). At
the backbone level, molecules G and H are very similar to each
other, both demonstrating a striking shift of the F-G helices,
with helix F shifting 3 Å away from the active site compared
with the closed conformation (Fig. 4). These three conformations have a progressive shift in the location of the side chain of
Phe-209 and a bimodal orientation of Phe-480, which open up
opposite sides of the channel. The flexibility of the Phe-480 side
chain is notable in that a similar torsion of Phe-480 is also
observed in the CYP2A13/2⫻NNK I422 structure (Fig. 4,
green). In the intermediate and open structures, reorientation
of Phe-300, Phe-118, and a bulge in helix I directly over the
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entation. Thus although the structure with two molecules is
overall most similar to the closed liganded conformation, the
flexibility of the ␤4 sheet system encompassing Phe-480 is
apparent.
In conclusion, the four structures herein of two different
human membrane cytochrome P450 enzymes provide valuable
information into the differential binding and metabolism of the
highly addictive human drug nicotine, as well as the selective
activation of a key tobacco procarcinogen responsible for lung
tumor initiation in smokers. For a variety of CYP2A ligands,
binding appears to be largely sterically controlled with Asn-297
as a key orienting feature. In addition, one structure of
CYP2A13 revealed its potential to simultaneously bind two
molecules of NNK. Finally, two previously undescribed conformations of CYP2A13 were elucidated in both nicotine and
NNK crystals, one with an open channel leading from the active
site to the protein surface between the F helix and ␤4 region and
one intermediate between this open conformation and the previously observed closed conformation.

FIGURE 5. Conformations of CYP2A13 and possible entry/exit scheme.
CYP2A13 was observed in four different conformations: closed with ligand
(CYP2A13 NNK P1), intermediate (CYP2A13 NNK P1, molecule G), open to the
surface (CYP2A13 NNK P1, molecule H), and closed with two NNK ligands
(CYP2A13 with NNK I4222). Solid black arrows between structures suggest a
continuum that would facilitate ligand entry/exit from the CYP2A13 active
site. The dashed arrow represents one possible route to the CYP2A13 structure with two ligands. Red arrows highlight differences between structures.
The single thick black arrow highlights the lobe of the channel connecting to
the protein surface.

heme are repositioned to reduce the active site volume near,
and ligand access to, Asn-297.
The conformations observed herein for CYP2A13 can be
used to suggest a trajectory for ligand entry/exit and the attendant structural changes as illustrated (Fig. 5). In the closed,
ligand-bound state, the F-G helices are in their lowered position, Phe-480 and Phe-209 close off exit from the active site, and
the positions of Phe-300, Phe-118, and helix I immediately over
the active site are compatible with ligand (nicotine or NNK)
hydrogen bonding to Asn-297 in orientations consistent with
the observed metabolites. In the intermediate conformation,
the F-G helices are raised, and the position of 209 begins to
open one side of the channel at the same time Phe-300, Phe290, and helix adopt orientations that occlude ligand interaction with Asn-297, but Phe-480 still largely closes off exit from
the active site. Finally, in the fully open conformation, the F-G
helices are still raised, and Phe-300, Phe-118, and part of the I
helix still occlude ligand access to Asn-297, but Phe-209 rotates
further and Phe-480 rotates dramatically to open up the channel from the active site to the protein surface. It is unclear where
the structure containing two NNK molecules fits within this
proposed continuum. The backbone of helices F-G and the
position of Phe-209 are clearly most similar to the closed conformation, but the positions of Phe-300 and Phe-118 are intermediate, and the position of Phe-480 is clearly in the open ori-
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